Survival impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in head and neck cancer.
Survival impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in head and neck cancer.
复制标题
DOI:
10.1002/hed.26809
复制
发表时间:
2021-11
期刊:
影响因子:
--
通讯作者:
Karam SD
中科院分区:
文献类型:
--
作者:
Stokes WA;Molina E;McDermott JD;Morgan RL;Bickett T;Fakhoury KR;Amini A;Karam SD
Preclinical evidence suggests a link between the renin-angiotensin system and oncogenesis. We aimed to explore the impact of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) in head and neck cancer (HNC). Over 5,000 patients were identified from the Surveillance, Epidemiology, and End Results-Medicare linked dataset and categorized according to ACEi and ARB and diagnoses of chronic kidney disease (CKD) or hypertension (HTN). Overall survival (OS) and cancer-specific survival (CSS) were compared using Cox multivariable regression (MVA), expressed as hazard ratios (HR) with 95% confidence intervals (95%CI). No significant MVA associations for OS or CSS were found for ACEi. Compared to patients with CKD/HTN taking ARB, those with CKD/HTN not taking ARB experienced worse OS (HR 1.28, 95%CI 1.09–1.51, p=0.003) and CSS (HR 1.23, 95% 1.00–1.50, p=0.050). ARB usage is associated with improved OS and CSS among HNC patients with CKD or HTN.
登录
查看更多内容
影响因子:
3.4
作者:
Kim, S. -A.;Moon, H.;Kim, S. Y.
通讯作者:
Kim, S. Y.
影响因子:
2.8
作者:
Liu JQ;Cai GY;Wang SY;Song YH;Xia YY;Liang S;Wang WL;Nie SS;Feng Z;Chen XM
通讯作者:
Chen XM
DOI:
10.1007/s00432-004-0582-7
发表时间:
2004-10-01
影响因子:
3.6
作者:
Yasumatsu, R;Nakashima, T;Komune, S
通讯作者:
Komune, S
影响因子:
4.7
作者:
Fujita, M;Hayashi, I;Majima, M
通讯作者:
Majima, M
影响因子:
7.2
作者:
Klabunde, CN;Potosky, AL;Warren, JL
通讯作者:
Warren, JL